These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 33443240)

  • 1. Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration.
    Palmieri B; Corazzari V; Panariello Brasile DG; Sangiovanni V; VadalÀ M
    Minerva Gastroenterol Dietol; 2020 Dec; 66(4):307-320. PubMed ID: 33443240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls.
    Da Silva HE; Arendt BM; Noureldin SA; Therapondos G; Guindi M; Allard JP
    J Acad Nutr Diet; 2014 Aug; 114(8):1181-94. PubMed ID: 24631112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of white button mushroom (Agaricus bisporus) against hepatic steatosis in ovariectomized mice as a model of postmenopausal women.
    Kanaya N; Kubo M; Liu Z; Chu P; Wang C; Yuan YC; Chen S
    PLoS One; 2011; 6(10):e26654. PubMed ID: 22046322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.
    Ferolla SM; Couto CA; Costa-Silva L; Armiliato GN; Pereira CA; Martins FS; Ferrari Mde L; Vilela EG; Torres HO; Cunha AS; Ferrari TC
    Nutrients; 2016 Jun; 8(7):. PubMed ID: 27367724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
    Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
    Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet.
    Wang C; Cui Y; Li C; Zhang Y; Xu S; Li X; Li H; Zhang X
    Lipids Health Dis; 2013 Nov; 12():165. PubMed ID: 24188280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease.
    Yamamoto M; Iwasa M; Iwata K; Kaito M; Sugimoto R; Urawa N; Mifuji R; Konishi M; Kobayashi Y; Adachi Y
    J Gastroenterol Hepatol; 2007 Apr; 22(4):498-503. PubMed ID: 17376040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.
    Rusu E; Jinga M; Enache G; Rusu F; Dragomir AD; Ancuta I; Draguţ R; Parpala C; Nan R; Sima I; Ateia S; Stoica V; Cheţa DM; Radulian G
    Nutr J; 2013 Aug; 12():119. PubMed ID: 23941362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
    Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M
    Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.
    Aigner E; Strasser M; Haufe H; Sonnweber T; Hohla F; Stadlmayr A; Solioz M; Tilg H; Patsch W; Weiss G; Stickel F; Datz C
    Am J Gastroenterol; 2010 Sep; 105(9):1978-85. PubMed ID: 20407430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan.
    Agarwal L; Aggarwal S; Shalimar ; Yadav R; Dattagupta S; Garg H; Agarwal S
    Obes Surg; 2021 Feb; 31(2):617-626. PubMed ID: 33052552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.